Stephen Unger analyst

Currently out of the existing stock ratings of Stephen Unger, 71 are a BUY (92.21%), 5 are a HOLD (6.49%), 1 are a SELL (1.3%).

Stephen Unger

Work Performance Price Targets & Ratings Chart

Analyst Stephen Unger, carries an average stock price target met ratio of 88.86% that have a potential upside of 29.21% achieved within 134 days. Previously, Stephen Unger worked at NEEDHAM.

Stephen Unger’s has documented 131 price targets and ratings displayed on 14 stocks. The coverage was on Healthcare, Technology, Industrials sectors.

Most recent stock forecast was given on NEO, NeoGenomics at 29-Mar-2022.

Wall Street Analyst Stephen Unger

Analyst best performing recommendations are on OCX (ONCOCYTE CORP).
The best stock recommendation documented was for OCX (ONCOCYTE CORP) at 11/13/2020. The price target of $4 was fulfilled within 68 days with a profit of $2.26 (129.89%) receiving and performance score of 19.1.

Average potential price target upside

BRKR Bruker BRKS Brooks Automation DHR Danaher NEO NeoGenomics TMO Thermo Fisher Scientific A Agilent Technologies CYRX Cryoport AZTA Azenta VCYT Veracyte GHDX Genomic Health MYGN Myriad Genetics OCX OncoCyte Corp PKI PerkinElmer PSNL Personalis

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Buy Since 06-Nov-2024

$50

$9.89 (24.66%)

$55

16 days ago
(13-Feb-2026)

5/10 (50%)

$13.49 (36.95%)

125

Buy Since 11-Feb-2016

$55

$14.89 (37.12%)

$48

2 months 14 days ago
(15-Dec-2025)

7/10 (70%)

$9.33 (20.43%)

277

Buy Since 20-May-2024

$60

$19.89 (49.59%)

$50

2 months 14 days ago
(15-Dec-2025)

1/4 (25%)

$14.33 (31.38%)

193

Buy Since 10-Dec-2025

$60

$19.89 (49.59%)

2 months 19 days ago
(10-Dec-2025)

0/1 (0%)

$13.08 (27.88%)

Hold Since 03-Aug-2021

$43

$2.89 (7.21%)

$45

3 months 25 days ago
(04-Nov-2025)

15/16 (93.75%)

$2.66 (6.59%)

236

Show more analysts

Please expand the browser size to see the chart

What Year was the first public recommendation made by Stephen Unger?

On 2018

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?